Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM702WR)

• Drug Name: LTC4 Drug Info
• Synonyms: leukotriene C4

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5280493
  ChEBI ID: CHEMBL451509
  CAS Number: CAS 72025-60-6
  TTD Drug ID: DM702WR
  INTEDE Drug ID: DR2048

Molecule-Related Drug Atlas

Drug(s) Targeting Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LTE4	DMCPB0Q	Discovery agent	N.A.	Investigative	[9]
UDP-glucose	DMLT4JA	Discovery agent	N.A.	Investigative	[4]
LTD4	DMIUZX3	Discovery agent	N.A.	Investigative	[4]
ASN04421891	DMC82XN	Discovery agent	N.A.	Investigative	[10]
ASN04450772	DMKR69T	Discovery agent	N.A.	Investigative	[10]
ASN06917370	DMA20JP	Discovery agent	N.A.	Investigative	[10]
ASN02563583	DMEO3Y4	Discovery agent	N.A.	Investigative	[10]
ASN04885796	DMQ0VZ8	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Leukotriene CysLT1 receptor (CYSLTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Montelukast	DMD157S	Allergic asthma	CA23.0	Approved	[11]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[12]
Pranlukast	DMYHDCA	Allergic rhinitis	CA08.0	Approved	[13]
Cinalukast	DMFIC0M	Asthma	CA23	Approved	[14]
KP-496	DMCO8UZ	Asthma	CA23	Phase 2	[15]
BAY-X-7195	DM2XE80	Asthma	CA23	Phase 2	[16]
Masilukast	DMDTI0L	Asthma	CA23	Phase 2	[17]
LM-1507.NA	DMW6VA0	Asthma	CA23	Phase 2	[18]
Iralukast	DMQ3RWN	Asthma	CA23	Phase 2	[19]
YM-57158	DMS31YW	Allergic rhinitis	CA08.0	Phase 1	[20]

Drug(s) Targeting Leukotriene CysLT2 receptor (CYSLTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY-X-7195	DM2XE80	Asthma	CA23	Phase 2	[16]
AS-35	DMC2WI7	Asthma	CA23	Discontinued in Phase 2	[21]
DS-4574	DM8GZWC	Asthma	CA23	Discontinued in Phase 2	[22]
Sulukast	DMBSLZV	Asthma	CA23	Discontinued in Phase 2	[23]
ICI-198615	DM0195G	Asthma	CA23	Terminated	[24]
MDL-43291	DMBIDQX	Asthma	CA23	Terminated	[25]
LY-290154	DMPZ7AO	Asthma	CA23	Terminated	[26]
FPL-55712	DMF1CDK	Asthma	CA23	Terminated	[27]
LTE4	DMCPB0Q	Discovery agent	N.A.	Investigative	[28]
LTD4	DMIUZX3	Discovery agent	N.A.	Investigative	[3]

Drug(s) Metabolized By Gamma-glutamyltranspeptidase 5 (GGT5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[5]
Glutathione ester	DMAV2I7	N. A.	N. A.	Investigative	[5]

Drug(s) Metabolized By Gamma-glutamyltranspeptidase 1 (GGT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glutathione ester	DMAV2I7	N. A.	N. A.	Investigative	[5]

Drug(s) Affected By Cysteinyl leukotriene receptor 1 (CYSLTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[8]
Pranlukast	DMYHDCA	Allergic rhinitis	CA08.0	Approved	[8]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[29]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[30]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[31]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[32]
PMID28870136-Compound-48	DMPIM9L	N. A.	N. A.	Patented	[29]
LTE4	DMCPB0Q	Discovery agent	N.A.	Investigative	[33]
BAYu9773	DMXQ14V	Discovery agent	N.A.	Investigative	[8]
CGP-57698	DMYZ72J	Discovery agent	N.A.	Investigative	[8]

Drug(s) Affected By ABC-type organic anion transporter ABCA8 (ABCA8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[34]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[35]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[37]
Indomethacin	DMSC4A7	Bursitis		Approved	[38]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[39]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[35]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[40]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[41]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[42]

Drug(s) Affected By ATP-binding cassette sub-family C member 6 (ABCC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzbromarone	DMC3YUA	Gout	FA25	Approved	[43]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[43]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[37]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[45]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[46]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[34]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[7]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[35]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[47]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukotriene CysLT1 receptor (CYSLTR1)	TTGKOY9	CLTR1_HUMAN	Agonist	[2]
Leukotriene CysLT2 receptor (CYSLTR2)	TT0PZR5	CLTR2_HUMAN	Agonist	[3]
Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)	TTMPART	GPR17_HUMAN	Agonist	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Gamma-glutamyltranspeptidase 5 (GGT5)	DEH6CAO	GGT5_HUMAN	Substrate	[5]
Gamma-glutamyltranspeptidase 1 (GGT1)	DEPT1ME	GGT1_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
ABC-type organic anion transporter ABCA8 (ABCA8)	OTCWLX6N	ABCA8_HUMAN	Regulation of Drug Effects	[6]
ATP-binding cassette sub-family C member 6 (ABCC6)	OTZT0LKT	MRP6_HUMAN	Regulation of Drug Effects	[7]
Cysteinyl leukotriene receptor 1 (CYSLTR1)	OT904HBN	CLTR1_HUMAN	Protein Interaction/Cellular Processes	[8]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3354).
• [2] Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999 Jun 24;399(6738):789-93.
• [3] Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000 Dec;58(6):1601-8.
• [4] The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006 Oct 4;25(19):4615-27.
• [5] Gamma-glutamyl compounds: substrate specificity of gamma-glutamyl transpeptidase enzymes. Anal Biochem. 2011 Jul 15;414(2):208-14.
• [6] Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
• [7] Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7.
• [8] A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lun... Mol Pharmacol. 2000 Jun;57(6):1182-9.
• [9] The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One. 2008;3(10):e3579.
• [10] In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52.
• [11] Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
• [12] Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
• [13] Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203.
• [14] Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5.
• [15] Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
• [16] The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
• [17] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [18] Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.
• [19] Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8.
• [20] In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
• [21] Inhibition of radiolabeled leukotriene-binding by AS-35 in guinea pig lung membrane fraction. Jpn J Pharmacol. 1992 Apr;58(4):357-64.
• [22] Inhibitory effect of DS-4574, a mast cell stabilizer with peptidoleukotriene receptor antagonism, on gastric acid secretion in rats. Eur J Pharmacol. 1994 Apr 1;255(1-3):229-34.
• [23] The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea-pig. Br J Pharmacol. 1989 Sep;98(1):259-67.
• [24] Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Biochem Pharmacol. 1992 Oct 6;44(7):1411-5.
• [25] Conformationally restricted leukotriene receptor antagonists: [(octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]ace tic acids. Pharmacology. 1990;40(5):271-6.
• [26] DOI: 10.1021/op060036x
• [27] Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat. Br J Pharmacol. 1991 Apr;102(4):865-70.
• [28] Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT agonist, N-methyl-leukotriene C in calcium reporter and beta arrestin assays. Mol Pharmacol. 2011 Feb;79(2):270-8.
• [29] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [30] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [31] Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. J Clin Immunol. 2007 Nov;27(6):613-9. doi: 10.1007/s10875-007-9115-x. Epub 2007 Jul 20.
• [32] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [33] Characterization of the leukotriene D4 receptor in dimethylsulphoxide-differentiated U937 cells: comparison with the leukotriene D4 receptor in human lung and guinea-pig lung. Eur J Pharmacol. 1993 Feb 15;244(3):239-50. doi: 10.1016/0922-4106(93)90149-4.
• [34] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [35] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [36] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [37] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [38] Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. J Appl Toxicol. 2015 Feb;35(2):205-18.
• [39] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [40] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [41] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [42] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [43] Multidrug resistance protein-6 (MRP6) in human dermal fibroblasts. Comparison between cells from normal subjects and from Pseudoxanthoma elasticum patients. Matrix Biol. 2003 Nov;22(6):491-500. doi: 10.1016/j.matbio.2003.09.001.
• [44] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [45] Expression of the human ABCC6 gene is induced by retinoids through the retinoid X receptor. Biochem Biophys Res Commun. 2006 Dec 1;350(4):1082-7. doi: 10.1016/j.bbrc.2006.10.007. Epub 2006 Oct 10.
• [46] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [47] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.